microRNAs are small non-coding RNAs that regulate several genes post-transcriptionally by
complementarity pairing. Since discovery, they have been reported to be involved in a …

As FDA-approved small RNA drugs start to enter clinical medicine, ongoing studies for the
microRNA (miRNA) class of small RNAs expand its preclinical and clinical research …

Glioblastoma multiforme (GBM) is one of the most fatal malignancies due to the existence of
blood-brain barrier (BBB) and the difficulty to maintain an effective drug accumulation in …

Temozolomide (TMZ) is a first-choice alkylating agent inducted as a gold standard therapy
for glioblastoma multiforme (GBM) and astrocytoma. A majority of patients do not respond to …

Glioblastoma (GBM) is a central nervous system tumor with poor prognosis due to the rapid
development of resistance to mono chemotherapy and poor brain targeted delivery …

Abstract PD-1/PD-L1 checkpoint blockades have achieved significant progress in several
kinds of tumours. Pembrolizumab, which targets PD-1, has been approved as a first-line …

Glioblastoma (GBM) is highly invasive and the deadliest brain tumor in adults. It is
characterized by inter-tumor and intra-tumor heterogeneity, short patient survival, and lack of …

Glioblastoma multiforme (GBM) is one of the most common, most formidable, and deadliest
malignant types of primary astrocytoma with a poor prognosis. At present, the standard of …

Simple Summary This review describes in a very detailed and exhaustive approach the
literature of these last 20 years on glioblastoma targeted therapies in Phases II-IV of 257 …

Cancer continues to be a leading threat to human health and life. Resistance to anti-cancer
drugs is a major impediment towards efficacious cancer treatment. p53 mutations play an …